跳至主要内容
临床试验/NCT06014801
NCT06014801招募中2 期

Low-Intensity Versus Medium-Intensity Continuous Kidney Replacement Therapy for Critically Ill Patients (LIMIT): A Multicenter Randomized Clinical Trial

Jikei University School of Medicine11 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2023年10月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
400
试验地点
11
主要终点
Composite of death and duration of kidney replacement therapy at 28 days

研究概览

简要总结

This clinical trial aims to investigate whether the low treatment intensity (12 mL/kg/hr, low-dose hemodialysis/filtration) or the medium treatment intensity (25 mL/kg/hr, standard-dose hemodialysis/filtration) is more effective and safer for continuous renal replacement therapy in critically ill patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient who meets all of the following criteria and who has given informed consent.
  • Adults (18 years of age or older, regardless of the time since ICU admission) currently admitted to an intensive care unit*.
  • *Includes high care units, where continuous monitoring is conducted and intensive care physicians are in charge of medical care.
  • A diagnosis of acute kidney injury is made according to the Kidney Disease: Improving Global Outcomes (KDIGO) international diagnostic criteria (one of the following is met)
  • Serum creatinine increased by more than 0.3 mg/dL within 48 hours
  • Serum creatinine increased more than 1.5-fold from baseline and the increase is considered to have occurred within 7 days
  • Oliguria (< 0.5 mL/kg/hr) lasting more than 6 hours
  • The treating intensivist believes that continuous kidney replacement therapy is necessary

排除标准

  • Patient who meets any of the following exclusion criteria will be excluded.
  • Receiving chronic dialysis or scheduled for initiation of chronic dialysis
  • Undergoing any kidney replacement therapy or blood purification therapy within 48 hours
  • When kidney replacement therapy using other dialysate or replacement fluids, such as citrate dialysis, is preferred due to coexisting bleeding disorders or allergy to acetate
  • Concomitant blood purification therapy other than hemofiltration/dialysis, such as plasma exchange
  • The patient is in a very critical condition and the treating physician believes that survival for more than 24 hours is unlikely
  • Previous participation in the study
  • After receiving a full explanation of the study and with full understanding, a patient do not consent to participate in the study of their own (or their substitute decision maker's) will.
  • The principal investigator (or an investigator) thinks it to be inappropriate to participate in this study.

研究组 & 干预措施

Medium intensity

Active Comparator

25 mL/kg/hr

干预措施: Dialysate fluid, Filtration replacement fluid (Drug)

Low intensity

Experimental

12 mL/kg/hr

干预措施: Dialysate fluid, Filtration replacement fluid (Drug)

结局指标

主要结局

Composite of death and duration of kidney replacement therapy at 28 days

时间窗: 28 days or hospital discharge whichever comes first

Composite endpoint of death and duration of kidney replacement therapy at 28 days

次要结局

  • Serum creatinine level at the end of kidney replacement therapy(90 days or hospital discharge whichever comes first)
  • 28-day ventilator-free days(28 days or hospital discharge whichever comes first)
  • 28-day vasopressor-free days(28 days or hospital discharge whichever comes first)
  • 24-hour urine output at the end of kidney replacement therapy(90 days or hospital discharge whichever comes first)
  • ICU mortality(90 days or hospital discharge whichever comes first)
  • Hospital mortality(90 days or hospital discharge whichever comes first)
  • Dialysis dependence at hospital discharge(90 days or hospital discharge whichever comes first)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tomoko Fujii

Professor

Jikei University School of Medicine

研究点 (11)

Loading locations...

相似试验